Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells $786,200.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Wim Souverijns sold 20,000 shares of the company’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $39.31, for a total value of $786,200.00. Following the completion of the sale, the insider owned 45,111 shares in the company, valued at $1,773,313.41. This trade represents a 30.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Wim Souverijns also recently made the following trade(s):

• On Tuesday, September 15th, Wim Souverijns sold 6,090 shares of Pharvaris stock. The stock was sold at an average price of $38.99, for a total value of $237,449.10.

Pharvaris Trading Down 1.9%

Shares of NASDAQ:PHVS traded down $0.73 during midday trading on Wednesday, hitting $37.33. The company had a trading volume of 426,621 shares, compared to its average volume of 403,904. Pharvaris N.V. has a 12 month low of $20.65 and a 12 month high of $43.25. The firm has a fifty day simple moving average of $35.27 and a 200 day simple moving average of $31.56. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of -12.24 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities analysts forecast that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PHVS has been the subject of a number of research reports. HSBC upgraded shares of Pharvaris to an “overweight” rating in a report on Thursday, August 13th. New Street Research set a $60.00 price target on shares of Pharvaris in a research report on Friday, August 14th. Wells Fargo & Company raised their price target on shares of Pharvaris from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Wednesday, September 9th. Rosenblatt Securities set a $60.00 target price on Pharvaris in a research report on Wednesday, September 9th. Finally, Wall Street Zen lowered Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Pharvaris currently has a consensus rating of “Moderate Buy” and an average target price of $59.87.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently modified their holdings of the business. Quantbot Technologies LP purchased a new stake in Pharvaris during the second quarter valued at about $41,000. CoreCap Advisors LLC acquired a new position in shares of Pharvaris in the 2nd quarter valued at about $93,000. Amundi lifted its stake in shares of Pharvaris by 12.0% in the 1st quarter. Amundi now owns 30,952 shares of the company’s stock valued at $874,000 after purchasing an additional 3,312 shares in the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Pharvaris during the 4th quarter worth about $139,000. Finally, Sofinnova Investments Inc. increased its position in Pharvaris by 0.7% during the 4th quarter. Sofinnova Investments Inc. now owns 745,169 shares of the company’s stock worth $20,678,000 after purchasing an additional 5,293 shares in the last quarter.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Phase III results for once-daily extended-release deucrictibant showed an 83% reduction in hereditary angioedema (HAE) attacks. The data support Pharvaris’ plans for regulatory submissions in 2027 and strengthen the commercial outlook for its lead drug candidate. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst sentiment remains favorable. The reported consensus price target increased 20.08% to $59.77, while recent targets include $62 from RBC and $65 from Wells Fargo and Leerink Partners. MarketBeat data shows a “Moderate Buy” consensus with an average target near $59.87. Pharvaris consensus price target raised
• Positive Sentiment: Institutional interest has expanded, with BlackRock establishing a position and Alyeska Investment Group and Seven Fleet Capital substantially increasing their holdings. Such buying can support investor confidence in PHVS.
• Neutral Sentiment: Pharvaris presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The event provided management with an opportunity to discuss deucrictibant and its regulatory strategy, but the supplied transcript headline does not identify a new announcement. Morgan Stanley Global Healthcare Conference transcript
• Negative Sentiment: Insiders have been selling shares. CEO Berndt Modig sold 2,291 shares worth approximately $90,265, while President Peng Lu sold 15,000 shares and Anne Lesage sold 30,000 shares worth about $1.15 million. Lu’s transaction was intended to cover tax withholding on vested equity, somewhat reducing its negative significance, but the overall selling may weigh on sentiment. Pharvaris insider selling report
• Negative Sentiment: Pharvaris remains unprofitable and previously reported quarterly EPS of negative $0.81, below the consensus estimate of negative $0.75. Analysts expect a full-year loss of approximately $3.12 per share, underscoring continued development and financing risk.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.